中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 10
Oct.  2022
Turn off MathJax
Article Contents

Association of JAK/STAT signaling pathway with portal vein thrombosis after splenectomy in cirrhotic patients with portal hypertension

DOI: 10.3969/j.issn.1001-5256.2022.10.012
Research funding:

Guiyang Science and Technology Planning Project ([2019]9-5-11)

More Information
  • Corresponding author: SHEN Xiaoxu, 512916746@qq.com(ORCID: 0000-0002-0055-6987)
  • Received Date: 2022-03-04
  • Accepted Date: 2022-04-29
  • Published Date: 2022-10-20
  •   Objective  To investigate the role of the Janus tyrosine kinase (JAK)- signal transducer and activators of transcription (STAT) signaling pathway in thrombosis formation after splenectomy in cirrhotic patients with portal hypertension.  Methods  A total of 198 liver cirrhosis patients with portal hypertension who underwent splenectomy and devascularization were recruited from March 2018 to April 2020 and then divided into thrombosis (n=41) and non-thrombosis groups (n=157) according to whether portal vein thrombosis occurred 3 months after surgery. mRNA levels of JAK2 and STAT3 in peripheral blood mononuclear cells (PBMCs) were assessed. Comparison of continuous data between groups was performed using t test, while comparison of categorial data between group was performed using chi square test. Clinicopathological data from patients were collected and analyzed for the potential risk factors of portal vein thrombosis by using univariate and multivariate Logistic regression analyses. The prediction values of JAK2 and STAT3 mRNA for portal vein thrombosis were evaluated by area under the receiver operating curve (AUC).  Results  The diameter of portal vein, the diameter of portal vein, the velocity difference of portal vein and the volume of spleen in the thrombus group were significantly higher than those in the non-thrombus group (t=4.718, 3.945, 8.671, and 2.006 respectively; P < 0.05).The relative mRNA levels of JAK2 and STAT3 in PBMCs of the two groups were significantly increased after surgery (t=12.933, 15.442, 14.386, 10.896; P < 0.05), and their levels were also much higher in the thrombosis group than in the non-thrombosis group of patients (P < 0.05). Multivariate Logistic regression analytic data showed that the portal vein diameter, the velocity difference of portal vein and mRNA level of JAK2 and STAT3 were all predictors for thrombosis in these patients (P < 0.05). The AUC of JAK2 and STAT3 mRNAs was 0.850 and 0.787, respectively in diagnosis of thrombosis in these patients.  Conclusion  The JAK / STAT signaling was activated in the process of thrombosis after splenectomy in cirrhotic patients with portal hypertension, which may be one of the important mechanisms of postoperative portal vein thrombosis, and may become a potential target for the prevention and treatment of postoperative portal vein thrombosis.

     

  • loading
  • [1]
    SIMONETTO DA, LIU M, KAMATH PS. Portal hypertension and related complications: diagnosis and management[J]. Mayo Clin Proc, 2019, 94(4): 714-726. DOI: 10.1016/j.mayocp.2018.12.020.
    [2]
    JIANG GQ, BAI DS, JIN SJ, et al. Modified vagus nerve-preserving versus conventional laparoscopic splenectomy and azygoportal disconnection for cirrhotic portal hypertension: a prospective randomized controlled trial[J]. Chin J Dig Surg, 2020, 19(12): 1280-1285. DOI: 10.3760/cma.j.cn115610-20201126-00741.

    蒋国庆, 柏斗胜, 金圣杰, 等. 改良保留迷走神经与传统腹腔镜脾切除联合贲门周围血管离断术治疗肝硬化门静脉高压症的前瞻性随机对照研究[J]. 中华消化外科杂志, 2020, 19(12): 1280-1285. DOI: 10.3760/cma.j.cn115610-20201126-00741.
    [3]
    HAN D, PENG JW, XIE HJ. Prevention of portal vein thrombosis in patients with cirrhotic portal hypertension aftersplenectomy and devascularization[J]. J Prac Hepatol, 2020, 23(3): 409-412. DOI: 10.3969/j.issn.1672-5069.2020.03.027.

    韩东, 彭经纬, 谢辉晋. 脾切除联合贲门周围血管离断术治疗肝硬化门脉高压症患者预防门静脉血栓形成研究[J]. 实用肝脏病杂志, 2020, 23(3): 409-412. DOI: 10.3969/j.issn.1672-5069.2020.03.027.
    [4]
    de FRANCHIS R, Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol, 2015, 63(3): 743-752. DOI: 10.1016/j.jhep.2015.05.022.
    [5]
    SONG ZM, DAI CL. Progress in diagnosis and treatment of portal vein thrombosis after splenectomy for cirrhosis and portal hypertension[J]. Chin J Curr Adv Gen Surg, 2019, 22(12): 958-962. DOI: 10.3969/j.issn.1009-9905.2019.12.009.

    宋子敏, 戴朝六. 肝硬化门脉高压症脾切除术后门静脉系统血栓形成的诊治进展[J]. 中国现代普通外科进展, 2019, 22(12): 958-962. DOI: 10.3969/j.issn.1009-9905.2019.12.009.
    [6]
    QI R, JIN X, SHI H, et al. Effect of laparoscopic splenectomy on portal vein thrombosis and serum YKL-40 in patients with cirrhotic portal hypertension[J]. Ann Hepatol, 2019, 18(6): 898-901. DOI: 10.1016/j.aohep.2019.06.009.
    [7]
    LI DY. Comparison of different intra-splenectomy splenic pedicle vascular treatments for postoperative portal vein thrombosis in cirrhotic portal hypertension[J]. Guangxi Med J, 2019, 41(8): 985-988. DOI: 10.11675/j.issn.0253-4304.2019.08.14.

    李丹阳. 肝硬化门静脉高压症脾切除术中不同脾蒂血管处理方法对术后门静脉血栓形成的对比研究[J]. 广西医学, 2019, 41(8): 985-988. DOI: 10.11675/j.issn.0253-4304.2019.08.14.
    [8]
    ZHANG XY, LI C, PENG W, et al. Platelet count-spleen volume ratio prediction of both moderate and severe portal hypertention in patients with cirrhosis by platelet count-spleen volume ratio[J]. J Abdominal Surg, 2016, 29(3): 187-192. DOI: 10.3969/j.issn.1003-5591.2016.03.009.

    张晓赟, 李川, 彭伟, 等. 血小板/脾脏体积比预测肝硬化门静脉高压症的严重程度[J]. 腹部外科, 2016, 29(3): 187-192. DOI: 10.3969/j.issn.1003-5591.2016.03.009.
    [9]
    XIONG ZJ, FAN HS, ZHU XN, et al. Application of FibroTouch combined with AST to platelet ratio index in diagnosis of portal hypertension in patients with hepatic cirrhosis[J/CD]. Chin J Hepat Surg(Electronic Edition), 2019, 8(4): 362-365. DOI: 10.3877/cma.j.issn.2095-3232.2019.04.019.

    熊志娇, 范红顺, 朱先女, 等. FibroTouch联合AST-血小板比值指数在肝硬化门静脉高压症诊断中的应用[J/CD]. 中华肝脏外科手术学电子杂志, 2019, 8(4): 362-365. DOI: 10.3877/cma.j.issn.2095-3232.2019.04.019.
    [10]
    SONG LJ, YUAN Y, WANG W. Clinical value of quantitative magnetic resonance imaging in the diagnosis of portal hypertension in patients with primary biliary cirrhosis[J]. J Prac Hepatol, 2020, 23(4): 568-571. DOI: 10.3969/j.issn.1672-5069.2020.04.029.

    宋丽俊, 袁雁, 王伟. 定量磁共振成像诊断原发性胆汁性肝硬化患者门静脉高压症价值分析[J]. 实用肝脏病杂志, 2020, 23(4): 568-571. DOI: 10.3969/j.issn.1672-5069.2020.04.029.
    [11]
    GIOIA S, NARDELLI S, PASQUALE C, et al. Natural history of patients with non cirrhotic portal hypertension: Comparison with patients with compensated cirrhosis[J]. Dig Liver Dis, 2018, 50(8): 839-844. DOI: 10.1016/j.dld.2018.01.132.
    [12]
    LYU SC, GU WQ. Research progress on prevention and treatment of portal vein thrombosis after splenectomy for patients with hepatic cirrhosis[J]. Chin J Hepatobiliary Surg, 2015, 21(1): 59-63. DOI: 10.3760/cma.j.issn.1007-8118.2015.01.019.

    吕少诚, 顾万清. 肝硬化患者脾切除术后门静脉血栓的防治研究进展[J]. 中华肝胆外科杂志, 2015, 21(1): 59-63. DOI: 10.3760/cma.j.issn.1007-8118.2015.01.019.
    [13]
    YANG S, HE C, FAN X, et al. Early prophylactic anticoagulation via transjugular intrahepatic route for portal vein thrombosis after splenectomy in cirrhotic portal hypertension[J]. J Vasc Interv Radiol, 2015, 26(7): 1009-1017. DOI: 10.1016/j.jvir.2015.03.008.
    [14]
    FENG Q, XU C, SUN MH. miR-141 inhibits thrombosis in vascular pathways through the TLR4 signaling pathway[J]. Med J West China, 2021, 33(2): 186-190. DOI: 10.3969/j.issn.1672-3511.2021.02.006.

    冯琦, 徐超, 孙明慧. miRNA-141通过调节TLR4信号通路抑制大鼠血栓形成[J]. 西部医学, 2021, 33(2): 186-190. DOI: 10.3969/j.issn.1672-3511.2021.02.006.
    [15]
    GU YN, XIE CY. Advancing investigate of deep vein thrombosis for inflammation and signa-ling pathway[J]. Chin J Immunol, 2020, 36(1): 113-118. DOI: 10.3969/j.issn.1000-484X.2020.01.022.

    顾燕妮, 谢春毅. 深静脉血栓形成炎症信号通路研究进展[J]. 中国免疫学杂志, 2020, 36(1): 113-118. DOI: 10.3969/j.issn.1000-484X.2020.01.022.
    [16]
    MALEMUD CJ. The role of the JAK/STAT signal pathway in rheumatoid arthritis[J]. Ther Adv Musculoskelet Dis, 2018, 10(5-6): 117-127. DOI: 10.1177/1759720X18776224.
    [17]
    BANERJEE S, BIEHL A, GADINA M, et al. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: Current and future prospects[J]. Drugs, 2017, 77(5): 521-546. DOI: 10.1007/s40265-017-0701-9.
    [18]
    LI Y, LI KH, WEN SH, et al. Role of JAK/STAT in intestinal injury induced by intestinal ischemia/reperfusion in rats[J]. Chin J Pathophysioly, 2011, 27(12): 2338-2344. DOI: 10.3969/j.issn.1000-4718.2011.12.019.

    李毅, 李坤河, 温仕宏, 等. JAK/STAT通路在大鼠肠缺血再灌注所致肠损伤中的作用[J]. 中国病理生理杂志, 2011, 27(12): 2338-2344. DOI: 10.3969/j.issn.1000-4718.2011.12.019.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(4)

    Article Metrics

    Article views (350) PDF downloads(30) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return